Originally published byEU-Startups
Cellply, a Bologna-based DeepTech startup developing analytical tools enabling a deep characterisation of cancer immunotherapies, cell therapies and cell-based biotherapeutics, has completed the largest portion of its latest funding round, securing €7.15 million to date. The investment was led by ENEA Tech e Biomedical, with additional participation from existing shareholders, including the SAFE conversion into […]
The post Bologna’s Cellply secures €7.15 million to develop tools for faster immunotherapy and cell therapy development appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Securing the Untrusted Agentic Development Layer
1d ago
Lovable is promising staff a 10% raise on their work anniversary. Here’s why it won’t catch on
7h ago
This browser add-in doesn't just hide ads, it tells you to OBEY
8h ago
Barcelona’s Dolfin raises €2.1 million Seed round to scale its AI-native platform for sales compensation
8h ago
Inside Legora’s hunt for legal tech acquisitions
13h ago